Adam Goulburn
Associate @ Lux Capital
New York, United States
Adam Goulburn is a Series A investor at Lux Capital in New York focused on Biotechnology and Medical. Adam Goulburn is based out of New York, New York and is the Founder & Managing Partner of Dimension Capital. Adam previously worked at Lux Capital as a Venture Partner. Adam Goulburn attended the Monash University.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Adam Goulburn invests in
Stages Adam Goulburn invests in
Countries Adam Goulburn invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (32%)
- Medical 5 (26%)
- Health Care 5 (26%)
- Software 2 (11%)
- Life Science 2 (11%)
Stage
- Series A 6 (32%)
- Seed 4 (21%)
- Series B 4 (21%)
- Series D 1 (5%)
- Post-IPO Equity 1 (5%)
Country
- United States 8 (42%)
- Canada 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $350.7M / Series D / Feb 26, 2025 | ||
| Kaleidoscope is a collaborative, cloud-based research platform for organizing and tracking scientific activities. | $6M / Seed / Sep 28, 2022 | ||
| Rivet is fixing the adversarial relationship between healthcare providers and payers, arming providers with more sophistication and productivity to improve financial transparency and operational efficiency. | $20.5M / Series B / Jun 21, 2022 | ||
| Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of truedrug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas. | $102M / Series B / Feb 23, 2022 | ||
| Gandeeva Therapeutics has developed a proprietary platform that combines innovative technologies across biochemistry, structural biology, imaging and machine learning to characterize protein-drug interactions at the atomic level, all designed to provide new insights into targeting protein function. | $40M / Series A / Jan 31, 2022 | ||
| Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $517.8M / Series B / Jan 06, 2022 | ||
| Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representativepatient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials. | $200M / Post-IPO Equity / Oct 07, 2021 | ||
| AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes develops a platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that enables patients to participate in treatment research online andbenefit from their own medical data. | $50M / Series B / Aug 24, 2021 | ||
| Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $148M / Series A / May 05, 2021 | ||
| Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of truedrug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas. | $35M / Series A / Jan 19, 2021 | ||
| See all 19 investments → | |||
Co-Investors
About Lux Capital
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Lux Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Kalish
General Partner
|
|||
Alex Nguyen
Principal
|
|||
Brandon Reeves
Partner
|
|||
Deena Shakir
General Partner
|
|||
Ian Peikon
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Adam Goulburn invest in?
Adam Goulburn invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Adam Goulburn?
Public channels for Adam Goulburn include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Adam Goulburn last invest?
The most recent investment recorded for Adam Goulburn closed in Feb 2025. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
